Nuvation Bio Inc.
NUVB
$4.39
-$0.12-2.56%
NYSE
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 698.96% | 1,137.19% | 900.35% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 698.96% | 1,137.19% | 900.35% | -- | -- |
| Cost of Revenue | 31.36% | 327.50% | 672.16% | -- | -- |
| Gross Profit | 6,642.64% | 2,173.29% | 4,393.18% | -- | -- |
| SG&A Expenses | 118.92% | 182.81% | 225.25% | 245.46% | 142.64% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 57.31% | 90.12% | 109.42% | 132.43% | 75.74% |
| Operating Income | -27.16% | -73.28% | -99.35% | -120.71% | -67.86% |
| Income Before Tax | 63.97% | 59.14% | 60.27% | -780.50% | -649.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 63.97% | 59.14% | 60.27% | -780.50% | -649.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 63.97% | 59.14% | 60.27% | -780.50% | -649.24% |
| EBIT | -27.16% | -73.28% | -99.35% | -120.71% | -67.86% |
| EBITDA | -26.64% | -72.89% | -99.15% | -120.24% | -67.54% |
| EPS Basic | 73.40% | 70.52% | 70.25% | -645.37% | -551.03% |
| Normalized Basic EPS | -15.83% | -47.44% | -68.15% | -93.18% | -49.70% |
| EPS Diluted | 73.31% | 70.42% | 70.15% | -640.38% | -551.75% |
| Normalized Diluted EPS | -15.83% | -47.44% | -68.15% | -93.18% | -49.70% |
| Average Basic Shares Outstanding | 27.16% | 42.07% | 43.05% | 36.31% | 22.70% |
| Average Diluted Shares Outstanding | 27.16% | 42.07% | 43.05% | 36.31% | 22.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |